BACKGROUND: The prognostic significance of age among pediatric patients with acute myeloid leukemia (AML) was investigated. METHODS: The authors reviewed the outcome of 424 patients who were <or=21 years of age at the time of diagnosis of AML (excluding acute promyelocytic leukemia) between 1983 and 2002 at St. Jude Children's Research Hospital (n=288) or the M. D. Anderson Cancer Center (n=136). Two treatment eras (1983-1989 and 1990-2002) were examined because of the greater intensity of treatment during the recent era. RESULTS: After controlling for the effects of cytogenetics, white blood cell (WBC) count, French-American-British (FAB) subtype, and treatment era, they observed that age and treatment era interacted significantly in relation to event-free survival (EFS) (P=.033). Patients 10 years of age or older were at greater risk of an adverse event than younger patients in the recent era (hazard ratio=1.8; 95% confidence interval [CI]: 1.3-2.6; P=.005) but not in the early era. The rate of adverse events (death or recurrence) increased significantly with each year of age in the recent era (4.3%/year; 95% CI: 1.9-6.8%; P=.001) but not in the early era. The rate of death increased significantly with each year of age in both eras (4.4%/year; 95% CI: 2.3-6.5%; P<.001). EFS and survival showed no association with study site, and the effects of age were similar at the 2 sites. CONCLUSIONS: These results suggest that age is an independent prognostic factor in childhood AML and that children younger than 10 years benefit more than older children from newer intensive therapies. Copyright (c) 2006 American Cancer Society.
BACKGROUND: The prognostic significance of age among pediatric patients with acute myeloid leukemia (AML) was investigated. METHODS: The authors reviewed the outcome of 424 patients who were <or=21 years of age at the time of diagnosis of AML (excluding acute promyelocytic leukemia) between 1983 and 2002 at St. Jude Children's Research Hospital (n=288) or the M. D. Anderson Cancer Center (n=136). Two treatment eras (1983-1989 and 1990-2002) were examined because of the greater intensity of treatment during the recent era. RESULTS: After controlling for the effects of cytogenetics, white blood cell (WBC) count, French-American-British (FAB) subtype, and treatment era, they observed that age and treatment era interacted significantly in relation to event-free survival (EFS) (P=.033). Patients 10 years of age or older were at greater risk of an adverse event than younger patients in the recent era (hazard ratio=1.8; 95% confidence interval [CI]: 1.3-2.6; P=.005) but not in the early era. The rate of adverse events (death or recurrence) increased significantly with each year of age in the recent era (4.3%/year; 95% CI: 1.9-6.8%; P=.001) but not in the early era. The rate of death increased significantly with each year of age in both eras (4.4%/year; 95% CI: 2.3-6.5%; P<.001). EFS and survival showed no association with study site, and the effects of age were similar at the 2 sites. CONCLUSIONS: These results suggest that age is an independent prognostic factor in childhood AML and that children younger than 10 years benefit more than older children from newer intensive therapies. Copyright (c) 2006 American Cancer Society.
Authors: Jeffrey E Rubnitz; Hiroto Inaba; Gary Dahl; Raul C Ribeiro; W Paul Bowman; Jeffrey Taub; Stanley Pounds; Bassem I Razzouk; Norman J Lacayo; Xueyuan Cao; Soheil Meshinchi; Barbara Degar; Gladstone Airewele; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; James R Downing; Wing Leung; Ching-Hon Pui; Dario Campana Journal: Lancet Oncol Date: 2010-05-05 Impact factor: 41.316
Authors: Yimei Li; Joanna G Newton; Kelly D Getz; Yuan-Shung Huang; Alix E Seif; Brian T Fisher; Richard Aplenc; Lena E Winestone Journal: Pediatr Blood Cancer Date: 2018-12-26 Impact factor: 3.167
Authors: Ditte J A Løhmann; Jonas Abrahamsson; Shau-Yin Ha; Ólafur G Jónsson; Minna Koskenvuo; Birgitte Lausen; Josefine Palle; Bernward Zeller; Henrik Hasle Journal: Haematologica Date: 2016-07-28 Impact factor: 9.941
Authors: Lena E Winestone; Kelly D Getz; Tamara P Miller; Jennifer J Wilkes; Leah Sack; Yimei Li; Yuan-Shung Huang; Alix E Seif; Rochelle Bagatell; Brian T Fisher; Andrew J Epstein; Richard Aplenc Journal: Am J Hematol Date: 2016-12-07 Impact factor: 10.047
Authors: Shannon L Maude; Julie C Fitzgerald; Brian T Fisher; Yimei Li; Yuan-Shung Huang; Kari Torp; Alix E Seif; Marko Kavcic; Dana M Walker; Kateri H Leckerman; Todd J Kilbaugh; Susan R Rheingold; Lillian Sung; Theoklis E Zaoutis; Robert A Berg; Vinay M Nadkarni; Neal J Thomas; Richard Aplenc Journal: Pediatr Crit Care Med Date: 2014-02 Impact factor: 3.624
Authors: Norman J Lacayo; Todd A Alonzo; Urte Gayko; David B Rosen; Matt Westfall; Norman Purvis; Santosh Putta; Brent Louie; James Hackett; Aileen Cleary Cohen; Alessandra Cesano; Robert Gerbing; Yaddanapudi Ravindranath; Gary V Dahl; Alan Gamis; Soheil Meshinchi Journal: Br J Haematol Date: 2013-05-20 Impact factor: 6.998
Authors: William G Woods; Anna R K Franklin; Todd A Alonzo; Robert B Gerbing; Kathleen A Donohue; Megan Othus; John Horan; Frederick R Appelbaum; Elihu H Estey; Clara D Bloomfield; Richard A Larson Journal: Cancer Date: 2013-09-19 Impact factor: 6.860